Clinical Trials

Clinical trial watch

Track phase updates, enrollment milestones, topline readouts, and study outcomes across the global drug development pipeline.

Hub signal

Search-friendly coverage

Keep the current route structure, but present it with the same premium hierarchy as the homepage.

Explore

Search-friendly hub pages

News

Pharma News

Daily pharmaceutical, biotech, medtech, and research coverage designed for search and discovery.

Open hub

Regulators

Regulatory Updates

FDA, EMA, PMDA, MHRA, and global regulatory coverage in one crawlable hub.

Open hub

Pipeline

Drug Pipeline

Regulatory pipeline signals, approvals, and market-moving development updates.

Open hub

Coverage

Latest indexed stories

11 stories in the current hub snapshot

🌍1d agoIndustryrelmada.com

Featured signal

Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated...

Publisher

Relmada Therapeutics

Limited excerpt on-platform. Click anywhere on this card to open the original publisher in a new tab.

Relmada Therapeutics· Original publisher link

Canonical metadata stays public, while full text remains on the original site.

🇬🇧1d agoRegulatorygov.uk

Guidance: Archiving and retention of clinical trial records

Information on clinical trial record retention and archiving requirements including requirements for...

MHRA UK· Original source

🇬🇧1d agoRegulatorygov.uk

Guidance: Declaration of Helsinki and Clinical Trial Regulations alignment

Information on the alignment of the amended UK clinical trial legislation with the Declaration of He...

MHRA UK· Original source

🌍1d agoRegulatorybioworld.com

Kintor’s KX-826 meets phase III endpoints in alopecia

Kintor Pharmaceutical Ltd.’s topical androgen receptor antagonist, pyrilutamide (KX-826), met the pr...

BioWorld NMPA RSS· Original source

🇬🇧1d agoIndustrygsk.com

Lynavoy (linerixibat) approved by the US FDA for cholestatic pruritus in patients with primary biliary cholangitis (PBC)

Approval based on the positive GLISTEN phase III trial with regulatory reviews underway in the EU, U...

GSK News· Original source

🇺🇸1d agoIndustryinvestor.lilly.com

Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes

For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 w...

Eli Lilly News· Original source

🇬🇧1d agoIndustryscrip.pharmaintelligence.informa.com

Kintor’s Male Hair Loss Drug Returns With Phase III Win

Kintor's topical androgen receptor inhibitor KX-826 posts win in China Phase III trial in male andro...

Scrip (Informa Intelligence)· Original source

🇯🇵1d agoIndustryshionogi.com

Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease

OSAKA, Japan, March 19, 2026 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Offi...

Shionogi· Original source

🇸🇪1d agoResearchnews.ki.se

New studyScreening improves early detection of colorectal cancerMore cases of colorectal cancer are detected at an early stage with screening, according to a randomised clinical trial by researchers at Uppsala University and Karolinska Institutet. The study has been published inNature Medicine.

More cases of colorectal cancer are detected at an early stage with screening, according to a random...

Karolinska Institutet (Press)· Original source

🇸🇪2d agoIndustrysobi.com

Results from EMBRACE Phase 2a study of emapalumab in interferon-gamma-driven sepsis presented at ISICEM

Primary endpoint: improvement in organ function observed in 60% of patients receiving high-dose emap...

Swedish Orphan Biovitrum· Original source

🌍2d agoIndustryinflarx.de

InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting

InflaRx· Original source